Helical has secured $10 million in seed funding to develop an innovative “virtual AI lab” aimed at transforming drug discovery processes for pharmaceutical teams. This London-based startup seeks to address the critical bottleneck in drug development, where over 90% of drug candidates fail during traditional testing phases. By leveraging advanced AI models trained on extensive biological datasets, Helical aims to streamline workflows, allowing scientists to test hypotheses digitally before moving to physical lab work.

The significance of Helical’s approach lies in its potential to revolutionize the drug discovery timeline. Current pharmaceutical R&D costs exceed $300 billion annually, with drug development often taking over a decade. Helical’s platform enables simultaneous exploration of multiple hypotheses, drastically reducing the time from hypothesis to decision-making—from months to days. This could lead to more efficient identification of viable drug candidates, particularly in complex fields like longevity research, where aging involves multifaceted biological processes rather than singular targets.

For longevity research, Helical’s system could fundamentally shift how scientists approach drug discovery. Traditional methods are often too linear and slow to effectively tackle the intricate network of aging-related mechanisms. By providing a platform that fosters collaboration between biologists and data scientists, Helical aims to enhance the reproducibility and reliability of in-silico experiments. This could lead to a more focused investigation on the mechanisms that significantly impact aging, ultimately accelerating the development of effective therapies. As Helical expands its collaborations and therapeutic focus, it positions itself as a key player in the emerging landscape of AI-driven longevity biotech, where the emphasis is shifting from mere hypothesis generation to the systematic delivery of validated drug candidates.

Source: longevity.technology